Connecting investors and companies

19:36

Life science analyst Antti Siltanen reveals some truths about investing in life science companies.

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio.

A robust distribution of funds to shareholders increases uncertainty regarding the reduction of financing costs.

Ren-Gas develops Power-to-Gas (P2G) solutions based on renewable e-methane production to reduce emissions from heavy transport and maritime traffic.

Sitowise announced on Tuesday that it would recognize an impairment of approximately 40 MEUR relating to its business in Sweden. While this impairment will not affect cash flow, it does reflect the prolonged challenges facing the Swedish business. The risk of a write-down was obvious, so the news came as no surprise and does not pressure us to change our operational estimates immediately.

Factory 02 will be the company's first large-scale facility, increasing its production capacity from the current 160 tons to 6,400 tons annually.

In recent years, the strategy has focused on selected industries, in selected growth markets, and on the own platform. The strategy resonates, but still requires proof of a breakthrough. Now the company must demonstrate a return to better organic growth and its scalability to profitability.

Bioretec updated its strategy and financial targets for 2026-28.

We have corrected assumptions in our forecast model regarding Control Resonant's assumed revenue sharing ratio with Annapurna for 2027-2028.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

28:25

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Aktia's earnings have risen significantly with interest rates, and the recovery in loan demand and steady growth in Asset Management should keep profitability relatively stable in the coming years.

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

The company cited delays in harvest season production as the reason for the profit warning.

The upcoming Control sequel is a critical release for Remedy's investment case, and we are confident in its success.

27:26

Tuukka Hirvonen, Head of Investor Relations, talks about pharmaceutical company Orion as an investment.

HomeMaid announced on Friday that its CEO, Stefan Högkvist, has sold 280,000 shares (at SEK 29 per share) in the company. The total value of the transaction amounted to 8.1 MSEK. Following this transaction, Stefan Högkvist’s holding in HomeMaid amounts to 155,000 shares (~0.8% of outstanding shares) and call options corresponding to 350,000 shares.